Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Apr 2008
Randomized Controlled Trial Comparative StudyComparison of single 2000-microg dose treatment vs. sequential repeated-dose 500-microg treatments with nebulized budesonide in acute asthma exacerbations.
High repeated doses of inhaled corticosteroids (ICSs) are recognized as having a more rapid improvement of outcomes than a single dose of ICS in severe acute asthma. However, to our knowledge, there has been no direct comparison of the early effects of single or repeated administration of the same total dosage of ICS in children with moderate to severe exacerbations of asthma. ⋯ The use of a single dose of nebulized budesonide is as effective as repeated administration of the same total dosage during the first 90 minutes before giving oral corticosteroids in children with moderate to severe exacerbations of asthma.
-
Ann. Allergy Asthma Immunol. · Nov 2006
Randomized Controlled Trial Multicenter StudyEffects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
Mometasone furoate dry powder inhaler (DPI) has been shown to effectively treat asthma in children. ⋯ Both mometasone furoate DPI doses were well tolerated and significantly improved lung function, maintained effective asthma control, and improved quality of life in children with asthma.
-
Ann. Allergy Asthma Immunol. · Jul 2006
Randomized Controlled Trial Comparative StudyRandomized trial of a comprehensive asthma education program after an emergency department visit.
Patients with asthma who visit the emergency department (ED) may benefit from education that optimizes self-management and treatment. ⋯ Delivery of a comprehensive AE program after an ED visit was ineffective in adult patients; however, it may be effective in children. Further research on alternative AE delivery strategies appears warranted to reduce the burden of asthma visits to the ED.
-
Ann. Allergy Asthma Immunol. · Jun 2006
Randomized Controlled TrialEfficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
Current asthma guidelines recommend inhaled glucocorticoids administered via pressurized metered-dose inhaler (MDI) with a holding chamber as the preferred therapy for young children with asthma. ⋯ Compared with placebo use, fluticasone propionate, 88 microg administered twice daily, significantly reduced asthma exacerbations, asthma symptoms, and rescue albuterol use and was well tolerated, with no clinically relevant systemic effects, as measured by growth velocity or 12-hour urinary cortisol excretion levels.
-
Ann. Allergy Asthma Immunol. · May 2006
Randomized Controlled Trial Multicenter StudyEfficacy and safety of roflumilast in the treatment of asthma.
The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. ⋯ These results support the emerging role of roflumilast, 500 microg/d, in the treatment of asthma.